0000811222
Company

Cardiff Lexington Corp

Services-Offices & Clinics of Doctors of Medicine · CDIX

follow-on effective OTC EFFECT

Filing Timeline

SEC EDGAR
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1/A and marks the registration effective.
2026-02-13 · 9999999995-26-000571
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
2026-02-05 · 0001683168-26-000787
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
2026-01-26 · 0001683168-26-000525
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
2026-01-20 · 0001683168-26-000426
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows RW in the pre-IPO sequence.
2025-12-15 · 0001683168-25-009164
RW withdrawn
Withdrawal request
Issuer requested withdrawal of the registration statement.
Follows S-1/A and ends the active registration process.
2025-05-02 · 0001683168-25-003049
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior FWP filing.
2024-06-18 · 0001683168-24-004287
FWP supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows S-1/A and supplements the active offering with updated prospectus details.
Cardiff Lexington Corp's current FWP filing outlines an IPO offering of $8 million in common stock at a price range of $4.00-$6.00, with the company focusing on its healthcare division following the 2021 acquisition of Nova Ortho and Spine. The filing highlights the company's strategic shift from diversified operations to a specialized orthopedic healthcare model, emphasizing growth opportunities in the aging population and increasing healthcare demand. The offering includes underwriters Craft Capital Management LLC and R.F. Lafferty & Co., Inc.
2024-06-17 · 0001683168-24-004255
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cardiff Lexington Corp's S-1/A filing reflects updates in response to SEC comments, focusing on capital structure details, convertible notes, and preferred stock classifications. The company addresses financial disclosures, including liabilities, ownership transitions, and restatements, while highlighting its operational and legal developments.
2024-06-12 · 0001683168-24-004135
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cardiff Lexington Corp's S-1/A filing represents an amendment to its initial IPO registration, likely addressing SEC comments. The document includes updated financial disclosures, with detailed classifications of preferred stock series, convertible notes, and liabilities. Key elements include restatements, changes in stockholder equity, and disclosures related to previous owners and settlements.
2024-05-31 · 0001683168-24-003912
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cardiff Lexington Corp's S-1/A filing reflects updates to its capital structure, including preferred stock series (Series N, R, X, I, J, L) and convertible notes payable. The company disclosed financial data through 2024-03-31, with adjustments related to restatements and ownership transitions. Key focus areas include senior convertible preferred stock, convertible debt instruments, and corporate governance disclosures.
2024-05-14 · 0001683168-24-003418
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cardiff Lexington Corp's S-1/A filing reflects amendments to its initial registration statement, focusing on updates to preferred stock structures, convertible notes, and restatements of financial data. The filing includes detailed disclosures about various preferred stock series, convertible debt instruments, and adjustments to equity accounts, indicating ongoing refinements to the company's capital structure ahead of its IPO.
2024-04-05 · 0001683168-24-002132
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
Cardiff Lexington Corp filed an S-1/A amendment to its initial registration statement on August 3, 2023, updating disclosures related to its capital structure, including preferred stock series, convertible notes, and financial instruments. The filing includes updated financial data and corporate governance details, with no visible narrative changes beyond technical amendments.
2023-08-03 · 0001683168-23-005255
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows S-1/A in the pre-IPO sequence.
Cardiff Lexington Corp's S-1 filing outlines its securities registration, including preferred stock series, common stock offerings, and financial segment disclosures. The filing references prior amendments (S-1/A) and includes technical financial data, but lacks detailed narrative about business operations, risks, or strategic changes. The company's structure involves multiple preferred stock classes and potential conversions, with a focus on regulatory compliance and offering details.
2023-07-19 · 0001683168-23-004994
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
Cardiff Lexington Corp. is a public holding company focused on acquiring niche businesses and commercial real estate. The S-1/A filing details an offering of 367,845,132 shares of common stock, with GHS Investments LLC as the selling stockholder. The company does not receive proceeds from the common stock sale but benefits from Series R Preferred stock sales. The offering is highly speculative, with limited trading volume and no guarantee of an active market.
2020-04-30 · 0001683168-20-001351
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
First tracked pre-IPO filing for this issuer.
Cardiff Lexington Corp. is registering 438 million shares of common stock through a selling stockholder, GHS Investments LLC, under a securities purchase agreement. The offering involves shares convertible from Series R Preferred Stock and aims to provide liquidity to the selling stockholder. The company, a holding company, focuses on acquiring niche businesses and commercial real estate, with no proceeds directly received from the common stock sale but potential proceeds from preferred stock transactions. The offering is highly speculative with limited market history and no guaranteed trading liquidity.
2020-01-21 · 0001683168-20-000193
Comparable Deals

2 comparable deals

Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 2 using nearest neighbors.
-14.2%
Median day-1
0%
Above issue
-20.3%
Median week-1
-20.9%
Downside (p10)

Recent News

No recent news stored for this issuer.